background
variou
virus
known
associ
pneumonia
howev
impact
viral
infect
adult
pneumonia
mortal
remain
unclear
studi
aim
clarifi
effect
viru
infect
pneumonia
mortal
among
adult
stratifi
viru
type
patient
comorbid
method
multicentr
prospect
studi
enrol
pneumonia
patient
age
year
septemb
august
sputum
sampl
test
inhous
multiplex
polymeras
chain
reaction
assay
identifi
respiratori
virus
viral
infect
statu
effect
inhospit
mortal
examin
age
group
comorbid
statu
result
total
patient
enrol
studi
age
year
comorbid
chronic
respiratori
diseas
comorbid
virus
detect
patient
human
rhinoviru
frequent
identifi
viru
follow
influenza
respiratori
syncyti
viru
respiratori
syncyti
viru
frequent
identifi
patient
chronic
respiratori
diseas
comorbid
without
comorbid
p
frequenc
virus
almost
ident
three
group
viru
detect
overal
associ
increas
mortal
adjust
risk
ratio
arr
ci
howev
influenza
viru
b
associ
threefold
higher
mortal
patient
chronic
respiratori
diseas
comorbid
arr
ci
intriguingli
paramyxovirus
associ
dramat
lower
mortal
patient
comorbid
arr
ci
chronic
respiratori
diseas
effect
affect
age
group
conclus
impact
viru
infect
pneumonia
mortal
vari
viru
type
comorbid
statu
adult
pneumonia
major
caus
morbid
mortal
among
adult
especi
elderli
manag
pneumonia
critic
problem
age
societi
like
japan
streptococcu
pneumonia
haemophilu
influenza
lead
bacteri
caus
adult
pneumonia
virus
also
play
import
role
diseas
develop
recent
advanc
molecular
diagnost
techniqu
enabl
us
detect
multipl
virus
simultan
studi
shown
viral
infect
common
pneumonia
patient
accord
recent
systemat
review
metaanalysi
virus
detect
respiratori
sampl
communityacquir
pneumonia
cap
patient
variou
virus
known
associ
respiratori
infect
includ
pneumonia
accord
systemat
review
influenza
commonli
detect
viru
cap
follow
human
rhinoviru
hrv
respiratori
syncyti
viru
rsv
human
coronaviru
hcov
addit
endem
respiratori
virus
emerg
respiratori
virus
sever
acut
respiratori
syndrom
coronaviru
middl
east
respiratori
syndrom
coronaviru
avian
influenza
pose
particularli
seriou
threat
global
health
secur
studi
suggest
emerg
viral
infect
associ
increas
risk
sever
condit
mortal
among
pneumonia
patient
must
note
pneumonia
mortal
vari
substanti
accord
patient
characterist
comorbid
aspir
risk
factor
physic
function
statu
establish
effect
control
measur
highprior
virus
patient
group
must
identifi
howev
preval
virus
adult
pneumonia
virusspecif
effect
clinic
outcom
remain
larg
unknown
best
knowledg
largescal
studi
investig
differ
effect
virus
pneumonia
mortal
patient
characterist
conduct
prospect
multicentr
studi
determin
distribut
virus
associ
pneumonia
adult
establish
virusspecif
effect
pneumonia
mortal
stratifi
age
group
comorbid
statu
adult
pneumonia
studi
groupjapan
apsgj
conduct
multicentr
prospect
hospitalbas
surveil
communityonset
pneumonia
four
communitybas
hospit
japan
previou
paper
burden
aetiolog
adult
pneumonia
report
base
data
clinic
sampl
collect
phase
studi
septemb
januari
current
studi
includ
data
sampl
collect
whole
studi
period
septemb
august
detail
studi
set
enrol
criteria
describ
previous
brief
outpati
inpati
screen
hospit
physician
elig
patient
identifi
use
standard
case
definit
patient
age
year
respiratori
symptom
compat
pneumonia
new
infiltr
shadow
chest
xray
comput
tomographi
scan
clinic
inform
collect
patient
medic
chart
use
standard
data
collect
form
sputum
blood
urin
sampl
collect
time
diagnosi
gram
stain
sputum
cultur
blood
cultur
perform
site
sputum
sampl
test
inhous
multiplex
polymeras
chain
reaction
pcr
assay
identifi
viral
bacteri
pathogen
institut
tropic
medicin
nagasaki
univers
legionella
pneumophila
test
use
multiplex
pcr
assay
detail
primer
pcr
method
use
describ
previous
urinari
antigen
test
perform
detect
pneumonia
l
pneumophila
binax
streptococcu
pneumonia
binax
legionella
aler
inc
waltham
usa
diagnosi
viral
infect
made
accord
pcr
result
bacteri
infect
diagnos
follow
criteria
fulfil
cultur
yield
pathogen
bacteria
microscop
purul
sputum
sampl
ie
geckler
classif
group
normal
steril
site
sampl
pcr
assay
posit
bacteri
dna
microscop
purul
sputum
sampl
urinari
antigen
test
show
posit
result
patient
categor
four
age
group
year
year
year
year
patient
disabl
statu
evalu
use
eastern
cooper
oncolog
group
perform
statu
ps
score
pneumonia
sever
assess
use
score
system
estim
effect
pneumonia
mortal
virus
categor
four
group
hrv
influenza
b
virus
paramyxovirus
rsv
hmpv
piv
type
virus
hadv
hbov
hcov
divid
patient
three
group
accord
comorbid
statu
patient
without
comorbid
patient
chronic
respiratori
diseas
patient
comorbid
chronic
respiratori
diseas
ie
comorbid
chronic
respiratori
diseas
includ
bronchial
asthma
chronic
obstruct
pulmonari
diseas
copd
interstiti
pneumonia
pneumoconiosi
bronchiectasi
comorbid
includ
diabet
mellitu
cerebrovascular
diseas
dementia
neuromuscular
diseas
cardiac
failur
ischaem
heart
diseas
collagen
diseas
malign
renal
diseas
liver
diseas
patient
consid
aspir
risk
factor
follow
factor
episod
aspir
presenc
dysphagia
conscious
disturb
neuromuscular
diseas
cerebrovascular
diseas
tube
feed
bedridden
statu
inhospit
death
defin
death
occur
hospit
first
year
studi
follow
patient
enrol
confirm
outpati
die
within
day
enrol
therefor
consid
inhospit
death
good
marker
shortterm
mortal
pneumonia
patient
regardless
hospit
statu
patient
categor
accord
comorbid
statu
ie
patient
without
comorbid
chronic
respiratori
diseas
comorbid
compar
use
chisquar
test
viral
bacteri
infect
statu
compar
age
group
comorbid
statu
use
chisquar
test
fisher
exact
test
chisquar
test
trend
inhospit
mortal
rate
calcul
viral
bacteri
infect
statu
compar
virusneg
group
effect
viral
infect
inhospit
mortal
express
risk
ratio
confid
interv
ci
estim
use
poisson
regress
model
robust
standard
error
age
studi
site
comorbid
statu
durat
symptom
month
diagnosi
antibiot
use
presenc
bacteria
consid
potenti
confound
base
prior
knowledg
includ
multipl
regress
model
patient
whose
onset
symptom
unknown
code
miss
valu
unknown
includ
patient
analysi
data
analys
use
stata
version
stata
corp
colleg
station
tx
usa
studi
approv
institut
review
board
irb
institut
tropic
medicin
nagasaki
univers
ebetsu
citi
hospit
kameda
medic
center
chikamori
hospit
juzenkai
hospit
requir
obtain
written
consent
particip
waiv
irb
studi
observ
natur
without
deviat
current
medic
practic
anonym
data
use
analys
studi
period
patient
enrol
studi
exclud
refus
particip
studi
n
absenc
pulmonari
infiltr
n
nonpneumonia
diagnosi
n
exclud
patient
whose
sputum
sampl
pcr
assay
unavail
patient
elig
analysi
fig
tabl
show
clinic
characterist
pneumonia
patient
comorbid
statu
approxim
patient
male
median
age
year
interquartil
rang
year
proport
patient
age
year
year
respect
patient
aspir
risk
factor
patient
comorbid
chronic
respiratori
diseas
comorbid
patient
comorbid
like
male
older
frequent
requir
hospit
frequent
develop
sever
diseas
frequent
aspir
risk
factor
higher
ps
score
visit
hospit
earlier
without
comorbid
proport
patient
aspir
risk
factor
particularli
high
among
patient
comorbid
multipl
symptom
frequent
observ
patient
chronic
respiratori
diseas
follow
without
comorbid
comorbid
total
patient
test
posit
least
one
viru
tabl
hrv
common
viru
identifi
n
follow
influenza
n
rsv
n
two
virus
detect
patient
frequent
combin
virus
hrv
plu
influenza
n
follow
hrv
plu
rsv
n
hrv
plu
hmpv
n
three
virus
hrv
hmpv
piv
type
detect
one
patient
bacteri
pathogen
detect
patient
viral
bacteri
pathogen
detect
patient
ie
viralbacteri
coinfect
viral
bacteri
infect
statu
compar
age
group
tabl
comorbid
statu
tabl
proport
overal
virusposit
pneumonia
differ
age
group
rsv
frequent
identifi
older
age
group
hcov
frequent
identifi
younger
age
group
proport
influenza
comorbid
includ
diabet
mellitu
cerebrovascular
diseas
dementia
neuromuscular
diseas
cardiac
failur
ischaem
heart
diseas
collagen
diseas
malign
renal
diseas
liver
diseas
posit
pneumonia
similar
across
age
group
bacteri
pathogen
frequent
identifi
younger
patient
patient
comorbid
statu
rsv
frequent
identifi
patient
chronic
respiratori
diseas
follow
comorbid
without
comorbid
p
frequenc
virus
almost
ident
three
group
tabl
bacteri
pathogen
frequent
identifi
patient
without
comorbid
comorbid
explor
symptom
patient
respiratori
viru
group
addit
file
tabl
proport
patient
multipl
symptom
ie
number
symptom
higher
patient
paramyxoviru
infect
without
viral
infect
vs
p
group
patient
aspir
risk
factor
paramyxoviru
like
cough
patient
without
viru
vs
p
among
patient
patient
die
discharg
overal
inhospit
mortal
mortal
among
virusposit
neg
group
respect
overal
effect
adjust
risk
ratio
arr
virus
mortal
ci
p
intriguingli
effect
specif
viru
type
analys
paramyxovirus
includ
rsv
hmpv
piv
type
associ
dramat
lower
mortal
arr
ci
p
among
paramyxovirusposit
pneumonia
five
die
three
rsvposit
one
hmpvposit
one
hmpvposit
enrol
rsv
alon
also
associ
lower
mortal
arr
ci
p
associ
reach
statist
signific
level
none
viru
type
associ
mortal
viru
typespecif
effect
investig
patient
stratifi
age
group
comorbid
statu
tabl
similar
effect
virus
seen
across
age
group
howev
influenza
viru
b
strongli
associ
higher
mortal
patient
chronic
respiratori
diseas
arr
ci
p
influenzarel
death
observ
without
comorbid
intriguingli
paramyxovirus
associ
markedli
lower
mortal
patient
comorbid
arr
ci
p
associ
observ
group
hrv
associ
mortal
three
group
viru
bacteria
virusand
bacteriaposit
pneumonia
demonstr
higher
mortal
virusand
bacterianeg
pneumonia
patient
chronic
respiratori
diseas
associ
reach
statist
signific
level
explor
associ
virus
inhospit
mortal
patient
aspir
risk
factor
addit
file
tabl
paramyxoviru
viru
type
significantli
associ
reduc
mortal
categori
patient
arr
ci
p
influenza
b
associ
mortal
arr
ci
p
mortal
higher
among
patient
cough
without
cough
vs
p
multicentr
prospect
studi
adult
pneumonia
associ
virus
hrv
lead
viru
identifi
follow
influenza
rsv
pattern
almost
ident
across
age
group
influenza
strongli
associ
higher
mortal
patient
chronic
respiratori
diseas
group
paramyxovirus
includ
rsv
hmpv
piv
type
associ
improv
surviv
patient
comorbid
especi
aspir
risk
factor
best
knowledg
studi
first
systemat
investig
virusspecif
effect
pneumonia
mortal
age
group
comorbid
statu
among
adult
virus
frequent
observ
pneumonia
patient
accord
previou
studi
virus
posit
cap
patent
us
norway
uk
china
respect
hrv
influenza
rsv
lead
virus
identifi
find
confirm
studi
howev
role
virus
pneumonia
develop
progress
fulli
establish
systemat
review
show
risk
death
higher
patient
viral
infect
although
associ
reach
statist
signific
level
odd
ratio
ci
major
limit
previou
studi
virus
patient
group
pool
may
overlook
intergroup
differ
fact
current
studi
virus
overal
associ
increas
mortal
among
pneumonia
patient
arr
ci
effect
differ
virus
patient
characterist
influenza
increas
pneumonia
mortal
ci
patient
chronic
respiratori
diseas
chang
mortal
patient
although
influenza
known
import
caus
pneumonia
death
studi
formal
compar
mortal
influenza
pneumonia
noninfluenza
pneumonia
find
inconsist
hand
previou
studi
demonstr
chronic
respiratori
diseas
increas
risk
sever
outcom
among
influenza
patient
bronchial
epitheli
cell
copd
suscept
replic
influenza
viru
impair
antivir
immun
thu
effect
influenza
diseas
progress
may
stronger
patient
condit
accord
cochran
review
influenza
vaccin
reduc
exacerb
patient
copd
season
influenza
vaccin
campaign
must
therefor
pay
special
attent
patient
group
interestingli
paramyxovirus
includ
rsv
associ
improv
surviv
patient
comorbid
inconsist
find
report
effect
paramyxovirus
pneumonia
sever
multin
studi
show
older
patient
infect
rsv
like
hospit
respiratori
virus
studi
conduct
us
demonstr
patient
rsv
infect
less
frequent
hospit
influenza
infect
retrospect
cohort
studi
conduct
hong
kong
show
mortal
rate
similar
adult
patient
hospit
rsv
season
influenza
inconsist
find
suggest
effect
paramyxoviru
infect
substanti
vari
patient
condit
fact
current
studi
compar
virusneg
pneumonia
mortal
paramyxovirusassoci
pneumonia
substanti
lower
among
patient
comorbid
find
observ
among
patient
without
comorbid
patient
chronic
respiratori
diseas
low
mortal
paramyxovirusassoci
pneumonia
group
may
associ
high
preval
multipl
symptom
studi
proport
patient
multipl
symptom
ie
number
symptom
higher
patient
paramyxoviru
infect
without
viral
infect
patient
paramyxovirusassoci
pneumonia
like
develop
symptom
probabl
like
visit
hospit
benefit
may
observ
patient
comorbid
group
patient
aspir
risk
factor
paramyxovirusassoci
pneumonia
like
cough
patient
without
viru
vs
p
mortal
higher
among
patient
cough
without
cough
vs
p
low
mortal
paramyxovirusassoci
pneumonia
patient
aspir
risk
factor
also
suggest
virus
may
stimul
cough
reflex
improv
patient
surviv
howev
studi
provid
conclus
evid
studi
need
unveil
mechan
potenti
benefit
paramyxoviru
infect
pneumonia
mortal
studi
multipl
virus
identifi
virusassoci
pneumonia
associ
higher
mortal
singl
viral
infect
patient
chronic
respiratori
diseas
comorbid
associ
multipl
viral
infect
pneumonia
mortal
remain
uncertain
systemat
review
shown
multipl
viral
infect
patient
respiratori
diseas
associ
diseas
sever
howev
major
previou
studi
includ
young
children
adult
effect
multipl
virus
diseas
progress
may
differ
children
adult
consist
previou
studi
half
viral
pneumonia
patient
coinfect
bacteri
pathogen
systemat
review
show
viralbacteri
coinfect
increas
mortal
howev
associ
observ
studi
viral
infect
lower
respiratori
tract
may
increas
risk
secondari
bacteri
infect
may
increas
risk
pneumonia
mortal
howev
sputum
sampl
collect
studi
thu
unabl
determin
time
cours
viral
bacteri
infect
cohort
studi
sequenti
respiratori
sampl
may
prefer
design
establish
causal
associ
viralbacteri
coinfect
pneumonia
mortal
advanc
molecular
diagnost
techniqu
enabl
viru
detect
clinic
set
find
rais
question
whether
pneumonia
patient
test
virus
increas
mortal
influenzaassoci
pneumonia
patient
chronic
respiratori
diseas
suggest
import
earli
diagnosi
influenza
initi
antivir
patient
group
hand
substanti
increas
mortal
found
virus
screen
virus
pneumonia
patient
may
unnecessari
clinic
set
studi
limit
first
sputum
sampl
avail
enrol
patient
howev
clinic
characterist
patient
without
sputum
sampl
differ
patient
sputum
sampl
exclus
group
affect
find
second
use
pcr
detect
virus
detect
viral
rna
dna
respiratori
sampl
alway
indic
presenc
causal
pathogen
particularli
detect
virus
nasopharyng
swab
may
reflect
lower
respiratori
infect
pneumonia
patient
therefor
use
sputum
sampl
pneumonia
patient
presenc
virus
lower
respiratori
tract
must
like
caus
third
due
natur
observ
studi
design
unmeasur
confound
factor
may
remain
risk
factor
analys
pneumonia
mortal
viral
infect
common
adult
pneumonia
impact
pneumonia
mortal
vari
virus
comorbid
variabl
impact
virus
popul
characterist
must
consid
develop
antivir
drug
vaccin
